IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Withdrawn – Currently Amended): A method of treating or preventing at least one disease selected from the group consisting of diabetes type II, obesity, and appetite regulation, in a subject in need thereof, comprising administering at least one aryl dicarboxamide of formula (I):



(I)

as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof, wherein:

A is an aminocarbonyl moiety of the formula –CO-NHR^6, wherein R^6 is ~~C_6-C_{15}-alkyl, C_2-C_{15}-alkenyl, C_2-C_{15}-alkynyl, a 3-8 membered cycloalkyl, C_1-C_6-alkyl-(3-8 membered) cycloalkyl,~~ a phenyl group attached directly or through an alkylene group, ~~C_1-C_{12}-alkyl phenyl, C_2-C_6-alkenyl phenyl, or C_2-C_6-alkynyl phenyl~~a phenyl-phenoxy group or an octyl group;

Cy is ~~an aryl, heteroaryl, aryl-heteroaryl, heteroaryl-aryl, aryl-aryl, cycloalkyl or heterocycle group~~a phenyl group or a thiazole-phenyl group;

n is either 0 or 1;

R^1 and R^2 are ~~independently from each other selected from the group consisting of~~ hydrogen ~~and C_1-C_6-alkyl~~;

R^3 is selected from the group consisting of: ~~C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_1-C_6-alkoxy, C_1-C_6-alkyl amine, C_1-C_6-alkyl alkoxy, aryl, heteroaryl, saturated or unsaturated 3-8-membered cycloalkyl, unsaturated 3-8-membered cycloalkyl, 3-8-membered~~

~~heterocycloalkyl, C_1-C_6-alkyl aryl, C_1-C_6-alkyl heteroaryl, C_2-C_6-alkenyl aryl, C_2-C_6-alkenyl heteroaryl, C_2-C_6-alkynyl aryl, C_2-C_6-alkynyl heteroaryl, C_1-C_6-alkyl cycloalkyl, C_1-C_6-alkyl heterocycloalkyl, C_2-C_6-alkenyl cycloalkyl, C_2-C_6-alkenyl heterocycloalkyl, C_2-C_6-alkynyl cycloalkyl, and C_2-C_6-alkynyl heterocycloalkyl~~ (i) an alkyl group optionally substituted with an amino group, or (ii) a cyclopentyl group, a cyclohexyl group, a phenyl group, or a pyridyl group, attached directly or through an alkylene group or an oxo group, and optionally substituted with a cyano group or a fluoromethyl group;

R^4 and R^5 are each independently from each other selected from the group consisting of H, ~~hydroxy, C_1-C_6-alkyl, carboxy, C_1-C_6-alkoxy, C_1-C_3-alkyl carboxy, C_2-C_3-alkenyl carboxy, C_2-C_3-alkynyl carboxy, and amino, or R^4 and R^5 may form an unsaturated or saturated heterocyclic ring, whereby at least one of R^4 or R^5 is not a hydrogen or C_1-C_6 alkyl~~OH, COOH, and OCH_2COOH;

to the subject in an amount sufficient to treat or prevent the at least one disease.

Claim 2 (Withdrawn): The method of claim 1, wherein the method is a method of treating.

Claim 3 (Withdrawn – Currently Amended): A method of treating or preventing at least one disease selected from the group consisting of diabetes, inadequate glucose tolerance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, and polycystic ovary syndrome, in a subject in need thereof, comprising, administering at least one aryl dicarboxamide of formula (I):



(I)

as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof, wherein:

A is an aminocarbonyl moiety of the formula –CO-NHR^6, wherein R^6 is ~~C_6-C_{15}-alkyl, C_2-C_{15}-alkenyl, C_2-C_{15}-alkynyl, a 3-8 membered-cycloalkyl, C_1-C_6-alkyl-(3-8 membered) cycloalkyl,~~ a phenyl group attached directly or through an alkylene group, ~~C_1-C_{12}-alkyl phenyl, C_2-C_6-alkenyl-phenyl, or C_2-C_6-alkynyl phenyl~~ a phenyl-phenoxy group, or an octyl group;

Cy is ~~an aryl, heteroaryl, aryl-heteroaryl, heteroaryl-aryl, aryl-aryl, cycloalkyl or heterocycle group~~a phenyl group or a thiazole-phenyl group;

n is either 0 or 1;

R^1 and R^2 are ~~independently from each other selected from the group consisting of~~ hydrogen ~~and C_1-C_6-alkyl~~;

R^3 is selected from the group consisting of: ~~C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_1-C_6-alkoxy, C_1-C_6-alkyl amine, C_1-C_6-alkyl alkoxy, aryl, heteroaryl, saturated 3-8-membered cycloalkyl, unsaturated 3-8-membered cycloalkyl, 3-8-membered heterocycloalkyl, C_1-C_6-alkyl aryl, C_1-C_6-alkyl heteroaryl, C_2-C_6-alkenyl aryl, C_2-C_6-alkenyl heteroaryl, C_2-C_6-alkynyl aryl, C_2-C_6-alkynyl heteroaryl, C_1-C_6-alkyl cycloalkyl, C_1-C_6-alkyl heterocycloalkyl, C_2-C_6-alkenyl cycloalkyl, C_2-C_6-alkenyl heterocycloalkyl, C_2-C_6-alkynyl cycloalkyl, and C_2-C_6-alkynyl heterocycloalkyl~~(i) an alkyl group optionally substituted with an amino group, or (ii) a cyclopentyl group, a cyclohexyl group, a phenyl group, or a pyridyl

group, attached directly or through an alkylene group or an oxo group, and optionally substituted with a cyano group or a fluoromethyl group;

R^4 and R^5 are each independently from each other selected from the group consisting of H, ~~hydroxy, C_1-C_6-alkyl, carboxy, C_1-C_6-alkoxy, C_1-C_3-alkyl carboxy, C_2-C_3-alkenyl carboxy, C_2-C_3-alkynyl carboxy, and amino, or R^4 and R^5 may form an unsaturated or saturated heterocyclic ring, whereby at least one of R^4 or R^5 is not a hydrogen or C_1-C_6 alkyl~~OH, COOH, and OCH_2COOH~~,~~;

to the subject in an amount sufficient to treat or prevent the at least one disease.

Claim 4 (Withdrawn): The method of claim 3, wherein the method is a method of treating.

Claim 5 (Canceled).

Claim 6 (Withdrawn – Currently Amended): A method of treating or preventing at least one metabolic disorder mediated by insulin resistance or hyperglycemia, in a subject in need thereof, comprising, administering at least one aryl dicarboxamide of formula (I):



(I)

as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof, wherein:

A is an aminocarbonyl moiety of the formula –CO-NHR^6, wherein R^6 is ~~C_6-C_{15}-alkyl, C_2-C_{15}-alkenyl, C_2-C_{15}-alkynyl, a 3-8 membered cycloalkyl, C_1-C_6-alkyl (3-8 membered)~~

~~cycloalkyl,~~ a phenyl group attached directly or through an alkylene group, ~~C_1-C_{12}-alkyl phenyl, C_2-C_6-alkenyl phenyl, or C_2-C_6-alkynyl phenyl~~ a phenyl-phenoxy group, or an octyl group;

Cy is ~~an aryl, heteroaryl, aryl-heteroaryl, heteroaryl-aryl, aryl-aryl, cycloalkyl or heterocycle group~~ a phenyl group or a thiazole-phenyl group;

n is either 0 or 1;

R^1 and R^2 are ~~independently from each other selected from the group consisting of~~ hydrogen ~~and C_1-C_6-alkyl~~;

R^3 is selected from the group consisting of: ~~C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_1-C_6-alkoxy, C_1-C_6-alkyl amine, C_1-C_6-alkyl alkoxy, aryl, heteroaryl, saturated 3-8-membered cycloalkyl, unsaturated 3-8-membered cycloalkyl, 3-8-membered heterocycloalkyl, C_1-C_6-alkyl aryl, C_1-C_6-alkyl heteroaryl, C_2-C_6-alkenyl aryl, C_2-C_6-alkenyl heteroaryl, C_2-C_6-alkynyl aryl, C_2-C_6-alkynyl heteroaryl, C_1-C_6-alkyl cycloalkyl, C_1-C_6-alkyl heterocycloalkyl, C_2-C_6-alkenyl cycloalkyl, C_2-C_6-alkenyl heterocycloalkyl, C_2-C_6-alkynyl cycloalkyl, and C_2-C_6-alkynyl heterocycloalkyl~~(i) an alkyl group optionally substituted with an amino group, or (ii) a cyclopentyl group, a cyclohexyl group, a phenyl group, or a pyridyl group, attached directly or through an alkylene group or an oxo group, and optionally substituted with a cyano group or a fluoromethyl group;

R^4 and R^5 are each independently from each other selected from the group consisting of H, ~~hydroxy, C_1-C_6-alkyl, carboxy, C_1-C_6-alkoxy, C_1-C_3-alkyl carboxy, C_2-C_3-alkenyl carboxy, C_2-C_3-alkynyl carboxy, and amino, or R^4 and R^5 may form an unsaturated or saturated heterocyclic ring, whereby at least one of R^4 or R^5 is not a hydrogen or C_1-C_6 alkyl,~~ OH, COOH, and OCH_2COOH;

to the subject in an amount sufficient to treat or prevent the at least one disorder.

Claims 7-9 (Cancelled)

Claim 10 (Currently Amended): An aryl dicarboxamide according to any of ~~the~~ formulae (Ia), (Ib) or (Ic):



(Ia) (Ib) (Ic)

wherein

A is an aminocarbonyl moiety of the formula –CO-NHR^6 wherein R^6 is ~~C_6-C_{15}-alkyl, C_2-C_{15}-alkenyl, C_2-C_{15}-alkynyl, a 3-8 membered cycloalkyl, C_1-C_6-alkyl-(3-8 membered) cycloalkyl,~~ a phenyl group attached directly or through an alkylene group,~~, C_1-C_{12}-alkyl phenyl, C_2-C_6-alkenyl phenyl, or C_2-C_6-alkynyl phenyl~~ a phenyl-phenoxy group, or an octyl group;

Cy is ~~an aryl, heteroaryl, aryl-heteroaryl, heteroaryl-aryl, aryl-aryl, cycloalkyl or heterocycle group~~ a phenyl group or a thiazole-phenyl group;

n is either 0 or 1;

R^1 and R^2 are ~~independently from each other selected from the group consisting of~~ hydrogen ~~and C_1-C_6-alkyl~~;

R^3 is selected from the group consisting of: ~~C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_1-C_6-alkoxy, C_1-C_6-alkyl amine, C_1-C_6-alkyl alkoxy, aryl, heteroaryl, saturated 3-8-membered cycloalkyl, unsaturated 3-8 membered cycloalkyl, 3-8-membered heterocycloalkyl, an acyl moiety, C_1-C_6-alkyl aryl, C_1-C_6-alkyl heteroaryl, C_2-C_6-alkenyl aryl, C_2-C_6-alkenyl heteroaryl, C_2-C_6-alkynyl aryl, C_2-C_6-alkynyl heteroaryl, C_1-C_6-alkyl~~

~~cycloalkyl, C_1-C_6-alkyl heterocycloalkyl, C_2-C_6-alkenyl cycloalkyl, C_2-C_6-alkenyl heterocycloalkyl, C_2-C_6-alkynyl cycloalkyl, and C_2-C_6-alkynyl heterocycloalkyl~~(i) an alkyl group optionally substituted with an amino group, or (ii) a cyclopentyl group, a cyclohexyl group, a phenyl group, or a pyridyl group, attached directly or through an alkylene group or an oxo group, and optionally substituted with a cyano group or a fluoromethyl group.

Claim 11 (Currently Amended): An aryl dicarboxamide according to formula (Ib) or (Ic):



wherein

A is an aminocarbonyl moiety of the formula –CO-NHR^6 wherein R^6 ~~is C_6-C_{15}-alkyl, C_2-C_{15}-alkenyl, C_2-C_{15}-alkynyl, a 3-8 membered cycloalkyl, C_1-C_6-alkyl (3-8 membered) cycloalkyl,~~ a phenyl group attached directly or through an alkylene group, ~~C_1-C_{12}-alkyl phenyl, C_2-C_6-alkenyl phenyl, or a C_2-C_6-alkynyl phenyl~~a phenyl-phenoxy group, or an octyl group;

Cy is ~~an aryl, heteroaryl, aryl-heteroaryl, heteroaryl-aryl, aryl-aryl, cycloalkyl or heterocycle group~~ a phenyl group or a thiazolyl-phenyl group;

n is either 0 or 1;

R^1 and R^2 are ~~independently from each other is selected from the group consisting of~~ hydrogen ~~and C_1-C_6-alkyl~~;

R^3 is selected from the group consisting of: ~~C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_1-C_6-alkoxy, C_1-C_6-alkyl amine, C_1-C_6-alkyl alkoxy, aryl, heteroaryl, saturated 3-8-membered cycloalkyl, unsaturated 3-8-membered cycloalkyl, 3-8-membered heterocycloalkyl, an acyl moiety, C_1-C_6-alkyl aryl, C_1-C_6-alkyl heteroaryl, C_2-C_6-alkenyl aryl, C_2-C_6-alkenyl heteroaryl, C_2-C_6-alkynyl aryl, C_2-C_6-alkynyl heteroaryl, C_1-C_6-alkyl cycloalkyl, C_1-C_6-alkyl heterocycloalkyl, C_2-C_6-alkenyl cycloalkyl, C_2-C_6-alkenyl heterocycloalkyl, C_2-C_6-alkynyl cycloalkyl, and C_2-C_6-alkynyl heterocycloalkyl~~(i) an alkyl group optionally substituted with an amino group, or (ii) a cyclopentyl group, a cyclohexyl group, a phenyl group, or a pyridyl group, attached directly or through an alkylene group or an oxo group, and optionally substituted with a cyano group or a fluoromethyl group.

Claims 12-14 (Cancelled)

Claim 15 (Currently Amended): An aryl dicarboxamide selected from the group consisting of :

5-[(3-cyclopentylpropanoyl)(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)amino]-2-hydroxybenzoic acid;

5-[(3-cyclopentylpropanoyl)(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)amino]-2-hydroxybenzoic acid;

[4-({{[2-(4-{[(4-pentylbenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}-[(2*E*)-3-phenylprop-2-enoyl]amino}methyl)phenoxy]acetic acid;

5-[(3-cyclopentylpropanoyl)(4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)amino]-2-hydroxybenzoic acid;

2-hydroxy-5-{(4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)[4-(trifluoromethyl)-benzoyl]amino}benzoic acid;

2-hydroxy-5-[[(4-{[(4-phenoxybenzyl)amino]carbonyl}-1,3-thiazol-2-yl)methyl](3-phenylpropanoyl)amino]benzoic acid;

5-{benzoyl[(4-{[(4-phenoxybenzyl)amino]carbonyl}-1,3-thiazol-2-yl)methyl]-amino}-2-hydroxybenzoic acid;

2-hydroxy-5-{[(4-{[(4-phenoxybenzyl)amino]carbonyl}-1,3-thiazol-2-yl)methyl][4-(trifluoromethyl)benzoyl]amino}benzoic acid;

5-[(cyclohexylcarbonyl)(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)amino]-2-hydroxybenzoic acid;

2-hydroxy-5-[(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)(3-phenylpropanoyl)-amino]benzoic acid;

5-[benzoyl(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)amino]-2-hydroxybenzoic acid;

5-[acetyl(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)amino]-2-hydroxybenzoic acid;

5-[(4-cyanobenzoyl)(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)amino]-2-hydroxybenzoic acid;

2-hydroxy-5-[(phenoxyacetyl)(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)-amino]-benzoic acid;

2-hydroxy-5-{(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)[4-(trifluoromethyl)-benzoyl]amino}benzoic acid;

2-hydroxy-5-{(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)[(2*E*)-3-phenylprop-2-enoyl]amino}benzoic acid;

5-[(N,N-dimethylglycyl)(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)amino]-2-hydroxybenzoic acid;

2-hydroxy-5-[(3-methylbut-2-enoyl)(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)-amino]benzoic acid;

2-hydroxy-5-{[{4-[(octylamino)carbonyl]benzyl}(phenoxyacetyl)amino]methyl}-benzoic acid;

2-hydroxy-5-({{4-[(octylamino)carbonyl]benzyl}[4-(trifluoromethyl)benzoyl]-amino}methyl)benzoic acid;

2-hydroxy-5-({{4-[(octylamino)carbonyl]benzyl}[(2*E*)-3-phenylprop-2-enoyl]-amino}methyl)benzoic acid;

5-{[(3-cyclopentylpropanoyl)(4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)-amino]methyl}-2-hydroxybenzoic acid;

2-hydroxy-5-{[(4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)(phenoxyacetyl)-amino]methyl}benzoic acid;

2-hydroxy-5-({(4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)[4-(trifluoromethyl)-benzoyl]amino}methyl)benzoic acid;

2-hydroxy-5-{[(3-methylbut-2-enoyl)(4-{[(4-pentylbenzyl)amino]carbonyl}-benzyl)amino]methyl}benzoic acid;

5-{[(3-cyclopentylpropanoyl)(4-{[(4-phenylbutyl)amino]carbonyl}benzyl)-amino]methyl}-2-hydroxybenzoic acid;

2-hydroxy-5-({[(4-{[(4-pentylbenzyl)amino]carbonyl}-1,3-thiazol-2-yl)methyl][(2*E*)-3-phenylprop-2-enoyl]amino}methyl)benzoic acid;

[4-({(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)[4-(trifluoromethyl)benzoyl]-amino}methyl)phenoxy]acetic acid;

2-hydroxy-5-[(4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)(3-phenylpropanoyl)-amino]benzoic acid;

4-[(3-cyclopentylpropanoyl)(4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)amino]-2-hydroxybenzoic acid;

2-hydroxy-4-{(4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)[4-(trifluoromethyl)-benzoyl]amino}benzoic acid;

2-hydroxy-5-[{[2-(4-{[(4-pentylbenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}(phenoxyacetyl)amino]benzoic acid;

2-hydroxy-5-{{[2-(4-{[(4-pentylbenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}[4-(trifluoromethyl)benzoyl]amino}benzoic acid;

5-([(6-chloropyridin-3-yl)carbonyl]{[2-(4-{[(4-pentylbenzyl)amino]carbonyl}-phenyl)-1,3-thiazol-4-yl]methyl}amino)-2-hydroxybenzoic acid;

5-((4-cyanobenzoyl){[2-(4-{[(4-pentylbenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}amino)-2-hydroxybenzoic acid;

2-hydroxy-5-((3-methylbut-2-enoyl){[2-(4-{[(4-pentylbenzyl)amino]carbonyl}-phenyl)-1,3-thiazol-4-yl]methyl}amino)benzoic acid;

5-((3-cyclopentylpropanoyl){[2-(4-{[(4-phenoxybenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}amino)-2-hydroxybenzoic acid;

2-hydroxy-5-{{[2-(4-{[(4-phenoxybenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}[4-(trifluoromethyl)benzoyl]amino}benzoic acid;

2-hydroxy-5-[{[2-(4-{[(4-phenoxybenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}(3-phenylpropanoyl)amino]benzoic acid;

5-(benzoyl{[2-(4-{[(4-phenoxybenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}amino)-2-hydroxybenzoic acid;

[4-({{[2-(4-{[(4-pentylbenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}[4-(trifluoromethyl)benzoyl]amino}methyl)phenoxy]acetic acid;

(4-{[{[2-(4-{[(4-pentylbenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}(3-phenylpropanoyl)amino]methyl}phenoxy)acetic acid;

[4-({{[2-(4-{[(4-phenylbutyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}[4-(trifluoromethyl)benzoyl]amino}methyl)phenoxy]acetic acid;

(4-{[{[2-(4-{[(4-phenylbutyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}(3-phenylpropanoyl)amino]methyl}phenoxy)acetic acid;

[4-({{[2-(4-{[(4-phenylbutyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}[(2*E*)-3-phenylprop-2-enoyl]amino}methyl)phenoxy]acetic acid;

{4-[((N,N-dimethylglycyl){[2-(4-{[(4-phenylbutyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}amino)methyl]phenoxy}acetic acid;

{4-[((cyclohexylcarbonyl){[2-(4-{[(4-phenylbutyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}amino)methyl]phenoxy}acetic acid;

{4-[((phenoxyacetyl){[2-(4-{[(4-phenoxybenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}amino)methyl]phenoxy}acetic acid;

[4-({{[2-(4-{[(4-phenoxybenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}[4-(trifluoromethyl)benzoyl]amino}methyl)phenoxy]acetic acid;

(4-{[{[2-(4-{[(4-phenoxybenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}(3-phenylpropanoyl)amino]methyl}phenoxy)acetic acid;

{4-[((cyclohexylcarbonyl){[2-(4-{[(4-phenoxybenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}amino)methyl]phenoxy}acetic acid;

[4-({[(2-{4-[(octylamino)carbonyl]phenyl}-1,3-thiazol-4-yl)methyl][4-(trifluoromethyl)benzoyl]amino}methyl)phenoxy]acetic acid; and

(4-{[[(2-{4-[(octylamino)carbonyl]phenyl}-1,3-thiazol-4-yl)methyl](3-phenylpropanoyl)amino]methyl}phenoxy)acetic acid.

Claim 16 (Previously Presented): A pharmaceutical composition comprising at least one aryl dicarboxamide according to claim 11 and a pharmaceutically acceptable carrier, diluent, excipient, or combination thereof.

Claim 17 (Previously Presented): A pharmaceutical composition comprising at least one aryl dicarboxamide according to claim 10 and a pharmaceutically acceptable carrier, diluent, excipient, or combination thereof.

Claim 18 (Withdrawn – Currently Amended): A method of preparing the aryl dicarboxamide of formula (I), comprising deprotecting, transforming, or deprotecting and transforming (I') to form the aryl dicarboxamide (Ia):



(I') (I)

wherein FG is A or a leaving group,

wherein:

A is an aminocarbonyl moiety of the formula –CO-NHR^6, wherein R^6 is ~~C_6-C_{15}-alkyl, C_2-C_{15}-alkenyl, C_2-C_{15}-alkynyl, a 3-8 membered cycloalkyl, C_1-C_6-alkyl-(3-8 membered) cycloalkyl,~~ a phenyl group attached directly or through an alkylene group, ~~C_1-C_{12}-alkyl phenyl, C_2-C_6-alkenyl phenyl, or C_2-C_6-alkynyl phenyl~~ a phenyl-phenoxy group, or an octyl group;

Cy is ~~an aryl, heteroaryl, aryl-heteroaryl, heteroaryl-aryl, aryl-aryl, cycloalkyl or heterocycle group~~ a phenyl group or a thiazole-phenyl group;

n is either 0 or 1;

R^1 and R^2 are ~~independently from each other is selected from the group consisting of~~ hydrogen ~~and C_1-C_6-alkyl~~;

R^3 is selected from the group consisting of: ~~C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_1-C_6-alkoxy, C_1-C_6-alkyl amine, C_1-C_6-alkyl alkoxy, aryl, heteroaryl, saturated 3-8-membered cycloalkyl, unsaturated 3-8-membered cycloalkyl, 3-8-membered heterocycloalkyl, C_1-C_6-alkyl aryl, C_1-C_6-alkyl heteroaryl, C_2-C_6-alkenyl aryl, C_2-C_6-alkenyl heteroaryl, C_2-C_6-alkynyl aryl, C_2-C_6-alkynyl heteroaryl, C_1-C_6-alkyl cycloalkyl, C_1-C_6-alkyl heterocycloalkyl, C_2-C_6-alkenyl cycloalkyl, C_2-C_6-alkenyl heterocycloalkyl, C_2-C_6-alkynyl cycloalkyl, and C_2-C_6-alkynyl heterocycloalkyl~~(i) an alkyl group optionally substituted with an amino group, or (ii) a cyclopentyl group, a cyclohexyl group, a phenyl group, or a pyridyl group, attached directly or through an alkylene group or an oxo group, and optionally substituted with a cyano group or a fluoromethyl group; and ~~wherein~~

R^4 and R^5 are each independently from each other selected from the group consisting of H, ~~hydroxy, C_1-C_6-alkyl, carboxy, C_1-C_6-alkoxy, C_1-C_3-alkyl carboxy, C_2-C_3-alkenyl carboxy, C_2-C_3-alkynyl carboxy, and amino, or R^4 and R^5 may form an unsaturated or saturated heterocyclic ring, whereby at least one of R^4 or R^5 is not a hydrogen or C_1-C_6-alkyl~~ OH, COOH, and OCH_2COOH.

Claims 19-27 (Cancelled)

Claim 28 (Withdrawn): The method of claim 6, wherein the method is a method of treating.